Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01466855
Other study ID # IARB1
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date October 2011
Est. completion date October 2015

Study information

Verified date February 2017
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC).

The goals of this study are:

- To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery)

- To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC

- To assess visual pathway function before and after the study therapy

- To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery


Recruitment information / eligibility

Status Terminated
Enrollment 36
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group N/A to 15 Years
Eligibility Inclusion Criteria:

1. Age: 15 years of age or younger

2. Diagnosis: Patients with untreated Group C/D/E unilateral Retinoblastoma at presentation without an indication for immediate enucleation (neovascular glaucoma or orbital pain) (Stratum A), or patients with a history of bilateral retinoblastoma and recurrent and/or refractory intraocular retinoblastoma where chemotherapy, external beam radiation and/or enucleation remain the only known option for disease control (Stratum B).

3. Therapeutic Options: Chemotherapy, External Beam Radiation therapy and/or Enucleation

4. Lansky = 50 for patients = 10 years of age; Karnofsky = 50 for patients > 10 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

5. Prior Therapy: Stratum A: No prior therapy is allowed. Stratum B: Patients must have local relapsed/refractory disease after receiving standard upfront therapy involving at least one chemotherapeutic regimen. There is no limit to prior chemotherapeutic regimens permitted. Prior radiation therapy is permitted.

6. Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, as described below:

- Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of study enrollment.

- Biologic therapies: Patients must not have received biologic anti-cancer agents within one week of study enrollment.

- Radiation therapy: Four weeks must have elapsed since external beam radiation therapy, if given.

7. Adequate Bone Marrow Function Defined as:

- Peripheral absolute neutrophil count (ANC) greater than or equal to 750/uL

- Platelet count greater than or equal to 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)

- Hemoglobin greater than or equal to 8.0 gm/dL (may receive RBC transfusions)

8. Adequate Renal Function Defined as:

-Maximum serum creatinine based on age as follows: 1 to < 2 years- 0.6 mg/dL; 2 to < 6 years - 0.8 mg/dL; 6 to < 10 years- 1 mg/dL; 10 to < 13 years- 1.2 mg/dL; 13 to 15 years- 1.5 mg/dL for boys and 1.4 mg/dL for girls.

OR

Creatinine clearance or radioisotope GFR greater than or equal to 70ml/min/1.73 m2

9. Adequate Liver Function Defined As:

- Bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 x upper limit of normal (ULN) for age

- SGPT (ALT) less than or equal to 5 x upper limit of normal (ULN) for age

- Serum albumin greater than or equal to 2 g/dL

10. Informed Consent: All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

11. Patients of child-bearing potential must have a negative pregnancy test and agree to use an effective birth control method (abstinence is an acceptable form of birth control).

Exclusion Criteria:

1. Extra-ocular retinoblastoma or retinoblastoma involving the anterior chamber

2. Retinoblastoma that could otherwise be treated with laser therapy, cryotherapy, or plaque therapy only

3. Structural brain abnormality

4. Uncontrolled infection, defined as requiring intravenous antibiotics at the time of enrollment

5. Concomitant Medications

- Growth factors that support platelet or white cell number or function must not have been administered within 3 days prior to enrollment.

- Patients who are currently receiving non-FDA approved drugs, or who have received a non-FDA approved drug within 7 days prior to enrollment, are ineligible.

- Patients who are currently receiving other anti-cancer agents are ineligible.

6. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intra-Ophthalmic Artery Topotecan Infusion
Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.

Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1-year event-free survival (event defined as the need for external beam radiation or enucleation) 1 year
Primary Response rate of retinoblastoma to topotecan when administered directly into the ophthalmic artery. EUA and retCAM imaging will be used to assess response rate. Up to 18 weeks
Primary Local (ocular) toxicities associated with the proposed regimen. Toxicities assessed using clinical examinations (EUA and Teller cards and Allan figures or Snellen visual acuity charts or other measures as appropriate for child's age.) For non-verbal infants we will employ Teller cards or Reacts to Light (if vision is too poor for Teller cards)
For pre-school age verbal toddlers/children we will employ LEA Symbols or HOTV, and possibly Allen figures
For older children capable of reading an alphabet we will employ Snellen visual acuity charts. Standard methods to assess color vision will also be employed when feasible.
Up to 12 months
Primary Patterns of response of retinoblastoma to topotecan when administered directly into the ophthalmic artery. Physical examination of the tumors will be recorded at baseline and at every tumor assessment visit. Tumors will be classified as having Type I, II, III, IV, V or O response based on characteristic features identified during physical examination. Up to 18 weeks
Secondary Visual pathway function Evaluation of visual pathway function will be measured using visual acuity, electroretinogram, visual evoked potential, and functional magnetic resonance imaging. Up to 12 months
Secondary Pharmacokinetics (Cmax and AUC) of topotecan when administered directly into the ophthalmic artery. Samples taken 15 and 60 minutes after topotecan administration on Day 1 of Cycle 1 (optional for patients)
Secondary Histologic findings in the eyes ultimately requiring enucleation. Any eye requiring enucleation will be assessed for the presence or absence of 'high risk' features defined as scleral or massive choroidal invasion of viable tumor, anterior chamber involvement, invasion of the optic nerve posterior to the lamina cribrosa, ciliary body or iris invasion. At time of enucleation, only if indicated
See also
  Status Clinical Trial Phase
Recruiting NCT04564521 - Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. N/A
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Withdrawn NCT01151748 - Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Active, not recruiting NCT00360750 - Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye N/A
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Enrolling by invitation NCT06227962 - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Terminated NCT02617862 - PCI Imaging System in Pediatric Ophthalmology N/A
Recruiting NCT02329002 - SPT Screening in Irradiated Hereditary Retinoblastoma Survivors N/A
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Completed NCT00002515 - Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT06367569 - Evaluation of MRI of the Pineal Gland in Retinoblastoma
Completed NCT02193724 - Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Completed NCT01884194 - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging N/A
Terminated NCT01393769 - Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Phase 2
Completed NCT00006246 - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Phase 1
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Withdrawn NCT00003273 - Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Phase 2